ConductScience.org, home

Paper36969889

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients.

Liu Z and 26 others. J Clin Transl Hepatol, 2023. Cited by 46 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients. Papers, record 36969889. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36969889

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients.
PubMed
Journal
J Clin Transl Hepatol
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
46
iCite
Relative citation ratio, by iCite
4.65
iCite
Revised in PubMed
2024-09-15
PubMed

Authors27

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu ZZhihonghttps://orcid.org/0000-0003-1142-3589
2Jin QQinglong
3Zhang YYuexin
4Gong GGuozhong
5Wu GGuicheng
6Yao LLvfeng
7Wen XXiaofeng
8Gao ZZhiliang
9Huang YYan
10Yang DDaokun
11Chen EEnqiang
12Mao QQing
13Lin SShide
14Shang JJia
15Gong HHuanyu
16Zhong LLihua
17Yin HHuafa
18Wang FFengmei
19Hu PPeng
20Wu QQiong

Source PubMed

See all 27 authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT03903796Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus InfectionDerived from the trialYes

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
131,400,968
Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics.
J Clin Densitom2019https://conductscience.org/library/papers/31400968PubMed
218,260,800Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system.AIDS Patient Care STDS2008https://conductscience.org/library/papers/18260800PubMed
331,237,366An Aging Population of Chronic Hepatitis B With Increasing Comorbidities: A Territory-Wide Study From 2000 to 2017.Hepatology2020https://conductscience.org/library/papers/31237366PubMed
428,792,763The ProTide Prodrug Technology: From the Concept to the Clinic.J Med Chem2018https://conductscience.org/library/papers/28792763PubMed
525,948,863Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.J Infect Dis2015https://conductscience.org/library/papers/25948863PubMed
625,525,197Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study.J Antimicrob Chemother2015https://conductscience.org/library/papers/25525197PubMed
731,606,734Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.Clin Infect Dis2020https://conductscience.org/library/papers/31606734PubMed
836,105,197Improved pharmacokinetics of tenofovir ester prodrugs strengthened the inhibition of HBV replication and the rebalance of hepatocellular metabolism in preclinical models.Front Pharmacol2022https://conductscience.org/library/papers/36105197PubMed
925,870,325The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial.Clin Infect Dis2015https://conductscience.org/library/papers/25870325PubMed
1019,414,839A new equation to estimate glomerular filtration rate.Ann Intern Med2009https://conductscience.org/library/papers/19414839PubMed
1120,495,438A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.AIDS2010https://conductscience.org/library/papers/20495438PubMed
1217,983,800Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B.Gastroenterology2007https://conductscience.org/library/papers/17983800PubMed
1312,460,055Fanconi syndrome and renal failure induced by tenofovir: a first case report.Am J Kidney Dis2002https://conductscience.org/library/papers/12460055PubMed
1432,522,576Performance of Indexed and Nonindexed Estimated GFR.Am J Kidney Dis2020https://conductscience.org/library/papers/32522576PubMed
1527,283,043Effects of nucleos(t)ide analogs on body composition in HBV-infected men: An age- and BMI-matched, cross-sectional study.Nutrition2016https://conductscience.org/library/papers/27283043PubMed
1620,648,555A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B.Hepatology2010https://conductscience.org/library/papers/20648555PubMed
1727,575,311The role of quantitative hepatitis B surface antigen revisited.J Hepatol2017https://conductscience.org/library/papers/27575311PubMed
189,242,686Parathyroid hormone-dependent degradation of type II Na+/Pi cotransporters.J Biol Chem1997https://conductscience.org/library/papers/9242686PubMed
1923,234,725Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study.Lancet2013https://conductscience.org/library/papers/23234725PubMed
2022,506,503Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B.Aliment Pharmacol Ther2012https://conductscience.org/library/papers/22506503PubMed

See all 34 references

Cited by39

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.

PMIDTitleJournalYearIn PapersSource
42,802,125[Effect of switching from entecavir to tenofovir amibufenamide on HBsAg levels in patients with chronic hepatitis B: a 96-week real-world study].Zhonghua Gan Zang Bing Za Zhi2026https://conductscience.org/library/papers/42802125PubMed
42,802,121[Expert recommendations on the first-line use and optimization plan of nucleos(t)ide analogues in the context of functional cure for chronic hepatitis B].Zhonghua Gan Zang Bing Za Zhi2026https://conductscience.org/library/papers/42802121PubMed
42,750,716Real-world effectiveness and safety of tenofovir amibufenamide in treatment-naïve chronic hepatitis B: a 48-week retrospective cohort study.Front Med (Lausanne)2026https://conductscience.org/library/papers/42750716PubMed
42,707,612Pradefovir mesylate and tenofovir amibufenamide for chronic hepatitis B: a systematic review and pragmatic treatment algorithm.Front Pharmacol2026https://conductscience.org/library/papers/42707612PubMed
42,106,615Effectiveness and safety of tenofovir amibufenamide in the treatment of chronic hepatitis B patients with low-level viremia: a retrospective real-world study.BMC Gastroenterol2026https://conductscience.org/library/papers/42106615PubMed
41,945,711A randomized, double-blind, phase 3, non-inferiority trial of pradefovir mesylate versus tenofovir disoproxil fumarate in Chinese patients with chronic hepatitis B.Hepatology2026https://conductscience.org/library/papers/41945711PubMed
41,828,677Accuracy of Diagnostic Investigations in Monitoring Hepatitis B Virus Infection: Strengths, Limitations, and Emerging Biomarkers.Int J Mol Sci2026https://conductscience.org/library/papers/41828677PubMed
41,312,460Effectiveness and safety of tenofovir alafenamide in chronic hepatitis B patients over 30 years old with positive hepatitis B virus DNA: a double-center retrospective study.Front Med (Lausanne)2025https://conductscience.org/library/papers/41312460PubMed
41,136,921Efficacy of TDF, TAF, TMF, and TDF-to-TAF switch in chronic hepatitis B: a network meta-analysis.BMC Gastroenterol2025https://conductscience.org/library/papers/41136921PubMed
41,060,358A Real-World Pharmacological Assessment of Tenofovir Amibufenamide and Tenofovir Alafenamide in 48-Week Chronic Hepatitis B Treatment: Efficacy, Safety, and Cost-Effectiveness.Curr Med Sci2025https://conductscience.org/library/papers/41060358PubMed
40,937,079Interim Analysis of 48-week Tenofovir Amibufenamide Treatment in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels: The PROMOTE Study.J Clin Transl Hepatol2025https://conductscience.org/library/papers/40937079PubMed
40,821,631Serum TNF-a and biomarkers levels after tenofovir therapy in patients with serum HBeAg-positive chronic hepatitis B.J Med Biochem2025https://conductscience.org/library/papers/40821631PubMed
40,691,459Current landscape of innovative drug development and regulatory support in China.Signal Transduct Target Ther2025https://conductscience.org/library/papers/40691459PubMed
40,678,712Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch.World J Gastroenterol2025https://conductscience.org/library/papers/40678712PubMed
40,390,028Recurrence risk factors for chronic hepatitis B virus-infected patients who achieve functional cure with pegylated interferon-α-2b-based therapy: a multicenter pilot study.Virol J2025https://conductscience.org/library/papers/40390028PubMed
40,248,094Effectiveness and safety of tenofovir amibufenamide and tenofovir alafenamide in treating elderly patients diagnosed with decompensated hepatitis B cirrhosis: a retrospective cohort study.Front Pharmacol2025https://conductscience.org/library/papers/40248094PubMed
40,093,664Tenofovir amibufenamide: A potential alternative for chronic hepatitis B treatment.World J Gastroenterol2025https://conductscience.org/library/papers/40093664PubMed
40,078,202Effectiveness and Safety of Tenofovir Amibufenamide in the Treatment of Chronic Hepatitis B: A Real-world, Multicenter Study.J Clin Transl Hepatol2025https://conductscience.org/library/papers/40078202PubMed
39,971,517[A case of chronic hepatitis B in the treatment of tenofovir amibufenamide].Zhonghua Gan Zang Bing Za Zhi2024https://conductscience.org/library/papers/39971517PubMed
39,971,513[A case of complete viral suppression after switching to tenofovir amibufenamide treatment with chronic hepatitis B and concomitant impaired renal function].Zhonghua Gan Zang Bing Za Zhi2024https://conductscience.org/library/papers/39971513PubMed

See all 39 cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FAS355PubTator's text mininghttps://conductscience.org/library/genes/355NCBI Gene
GPT2,875PubTator's text mininghttps://conductscience.org/library/genes/2875NCBI Gene
HBE13,046PubTator's text mininghttps://conductscience.org/library/genes/3046NCBI Gene
PTH5,741PubTator's text mininghttps://conductscience.org/library/genes/5741NCBI Gene

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
TENOFOVIR DISOPROXIL FUMARATECHEMBL1486Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1486

Source ChEMBL

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36969889

GET https://conductscience.org/api/papers/v1/36969889/authors?page=2